November 09, 2013
Relypsa Reports the Presentation of its Two-Part Pivotal Phase 3 Patiromer Trial in ASN Late-Breaker Poster

October 21, 2013
Relypsa to Present Phase 3 Data in Late-Breaking Poster Session at ASN Kidney Week 2013 Annual Meeting In Atlanta, GA

October 17, 2013
Relypsa Reports Positive Topline Results for its 52-Week Phase 2b Trial of Patiromer

October 10, 2013
Relypsa Reports Positive Top-Line Results for the Second Part of its Two-Part Pivotal Phase 3 Trial of Patiromer

September 26, 2013
Relypsa adds Renal Industry Veteran John P. Butler to Board of Directors

September 10, 2013
Relypsa reports positive top-line results for the first part of its two-part pivotal phase 3 trial of patiromer

May 15, 2013
Relypsa Announces Appointment of John Orwin as Chief Executive Officer

May 13, 2013
Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia

February 20, 2013
Relypsa Enrolls Initial Patient in Pivotal Phase 3 Program for the Treatment of Hyperkalemia

January 02, 2013
Relypsa Announces Agreement with FDA on Special Protocol Assessment for Patiromer Phase 3 Trial for the Treatment of Hyperkalemia

January 02, 2013
Relypsa Announces Changes to Board of Directors

December 10, 2012
Kristine M. Ball Joins Relypsa as Senior Vice President, Chief Financial Officer

August 15, 2012
Relypsa Announces $80 Million Private Financing Transaction

February 08, 2012
Lance Berman, M.D. Joins Relypsa as Senior Vice President, Commercial Strategy & Medical Affairs

October 25, 2011
Wilhelm Stahl, Ph.D. Joins Relypsa as Senior Vice President, Pharmaceutical Operation

June 28 , 2011
Relypsa Begins Treatment in AMETHYST-DN Trial of RLY5016 for Hyperkalemia in Diabetic Nephropathy Patients with Chronic Kidney Disease

May 23, 2011
Relypsa Announces Presentation of Positive Phase 2 Results for RLY5016 at American Society of Hypertension Meeting

May 19, 2011
Relypsa Adds Key Leadership Positions to Support Late-Stage Development and Pre-Launch Commercial Activities

September 15, 2010
Positive Phase 2 Data for RLY5016 Presented in Late-Breaker Session at Heart Failure Society of America Meeting

September 13, 2010
Relypsa Raises $70 Million in Series B - Financing; Funds to Support Late-Stage Development of RLY5016 - New Board Members Announced

August 29, 2010
ESC 2010: Hot Line I: New oral potassium binder lowers potassium levels in patients with heart failure and heart failure with chronic kidney disease

June 16, 2010
Relypsa Initiates Open-Label Phase 2 Clinical Study of RLY5016 for the Management of Hyperkalemia

June 16, 2010
Relypsa Appoints Claire J. Lockey Vice President, Regulatory Affairs

October 7, 2009
Relypsa Initiates Phase 2b Clinical Trial of RLY5016 for the Prevention of Hyperkalemia in Heart Failure Patients

January 9, 2008
Relypsa appoints Ronald A. Krasnow Senior Vice President, Intellectual Property and Chief Patent Counsel

October 29, 2007
Relypsa formed with $33 Million Series A Funding to discover and develop polymeric drugs

louis vuitton outlet Louis Vuitton Outlet michael kors outlet jordan 3 sport blue michael kors outlet louis vuitton outlet jordan 3 wolf grey sport blue 6s sport blue 3s Cheap Oakley Sunglasses michael kors outlet jordan 6 sport blue Louis Vuitton Outlet Michael Kors Outlet louis vuitton outlet kate spade diper bag sport blue 3s Michael Kors Outlet sport blue 6s louis vuitton outlet